

# AMGEN INC.

ISIN: US0311621009 WKN: 031162100 Asset Class: Stock

## Company

2023/02/03 22:00:00

Price

**245.17**

USD

Difference

**-0.55%(-1.36)**

## Contact Details

AMGEN INC.

Tel: 1-805-447-1000

--

Fax: 1-805-447-1010

One Amgen Center Drive

Web: <http://www.amgen.com>

91320-1799 Thousand Oaks

E-mail: -



## Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	22,186,000,000	-	19,385,000,000	32,096,000,000	21,144,000,000	31,802,000,000
<b>Common stock capital</b>	-	-	-	-	-	-
<b>Fixed assets</b>	42,935,000,000	-	41,780,000,000	-	41,804,000,000	-
<b>Equity capital of a company</b>	-	3,661,000,000	-	6,700,000,000	-	9,409,000,000
<b>Cash and cash equivalents</b>	9,305,000,000	-	7,989,000,000	-	6,266,000,000	-
<b>Accrued liabilities</b>	-	5,757,000,000	-	6,594,000,000	-	6,968,000,000
<b>Other assets</b>	-	-	-	-	-	-
<b>Current liabilities</b>	-	15,687,000,000	-	12,184,000,000	-	11,653,000,000
<b>Prepayments and accrued income</b>	-	-	-	-	-	-
<b>Non-current liabilities</b>	-	45,773,000,000	-	42,281,000,000	-	41,886,000,000
<b>Different income</b>	-	-	-	-	-	-
<b>Other liabilities</b>	-	2,662,000,000	-	1,940,000,000	-	1,717,000,000
<b>Total assets</b>	65,121,000,000	65,121,000,000	61,165,000,000	61,165,000,000	62,948,000,000	62,948,000,000

## Balance notes

	2022	2021	2020
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	-	24,200	24,300
<b>Equity ratio</b>	5.62%	10.95%	14.95%
<b>Debt-equity ratio</b>	1,678.78%	812.91%	569.02%

## Others

	2022	2021	2020
<b>Tax Expense Rate</b>	10.81%	12.06%	10.68%

# AMGEN INC.

ISIN: US0311621009 WKN: 031162100 Asset Class: Stock

## Income statement

	2022	2021	2020
Turnover	26,323,000,000	25,987,000,000	25,246,000,000
Net income	6,552,000,000	5,893,000,000	7,264,000,000
EBIT	6,737,016,600	7,324,877,700	8,754,636,600
Operating income before taxes	7,346,000,000	6,701,000,000	8,133,000,000
Cash Flow	9,721,000,000	9,261,000,000	10,497,000,000
Net interest income	-	-1,286,000,000	-1,413,000,000
Research and development expenses	4,341,000,000	4,819,000,000	4,207,000,000
Income taxes	794,000,000	808,000,000	869,000,000
Result from investments in subsidiaries, associates and other	-	0	0
Revenues per employee	-	984,821	952,803

## Board of Directors

## Members of Management Board

Brian Druker	Member of Board of Directors
Michael Drake	Member of Board of Directors
Omar Ishrak	Member of Board of Directors
Robert Williams	Member of Board of Directors
Ronald Sugar	Member of Board of Directors
Tyler Jacks	Member of Board of Directors
Wanda Austin	Member of Board of Directors
Amy Miles	Member of Board of Directors
Charles Holley	Member of Board of Directors
Ellen Kullman	Member of Board of Directors
Greg Garland	Member of Board of Directors
Robert Eckert	Member of Board of Directors
Robert Bradway	Chairman of Managing Board
Annalisa Pizzarello	Member of Executive Committee
Anton Rabushka	Member of Executive Committee
Arleen Paulino	Member of Executive Committee
Darryl Sleep	Member of Executive Committee
David A. Piacquad	Member of Executive Committee
David M. Reese	Member of Executive Committee
Esteban Santos	Member of Executive Committee